Athira Pharma
 | |
| Nasdaq: ATHA | |
| Industry | Biotechnology, Pharmaceuticals |
| Founded | 2011 |
| Headquarters | , United States |
| Products | ATH-1017 |
| Website | www |
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.[1]
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.[2][3][4]
Leen Kawas served as the company's first President and CEO,[5] but resigned in October 2021,[6] after an independent special committee found she "altered images in scientific papers she authored."[7] On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.[7]
History
[edit]The company has received financial support from venture capitalist groups and angel investors through four rounds of funding to date. [8] Athira Pharma was known as M3 Biotechnology until it underwent a name change on April 11, 2019.[9][10]
Core technology
[edit]The company's lead asset, ATH-1017, is in human trials of Alzheimer's disease as of 2021.[11] ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function.[12] It aims to regenerate lost connections in the brain, protect brain cells from further damage, and prevent additional neuronal deterioration. [13] ATH-1017 is currently being tested in two clinical studies: ACT-AD and LIFT-AD.[14]
References
[edit]- ^ "Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update". Athira Pharma. 2021-08-16. Retrieved 2021-10-20.
- ^ "ADDF Funding Advances M3 Biotechnology Toward Clinical Trials | Alzheimer's Drug Discovery Foundation". www.alzdiscovery.org. Retrieved 2018-10-15.
- ^ "First Trial of Alzheimer's Drug Underway | Science and Enterprise". sciencebusiness.technewslit.com. 17 October 2017. Retrieved 2018-10-15.
- ^ "Individual Grants | Life Sciences Discovery Fund". www.lsdfa.org. Retrieved 2018-07-31.
- ^ "Entrepreneurship has grown on M3 Biotechnology's CEO". The Seattle Times. 2017-04-30. Retrieved 2018-07-31.
- ^ "Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer". Athira Pharma - Company Press Releases. October 21, 2021. Retrieved July 10, 2022.
- ^ a b Soper, Taylor (October 21, 2021). "Ex-Athira Pharma CEO Leen Kawas resigns and leaves board after image manipulation investigation". GeekWire. Archived from the original on October 21, 2021. Retrieved July 10, 2022.
- ^ "M3 Biotechnology Company Profile: Valuation & Investors | PitchBook". pitchbook.com. Retrieved 2018-10-15.
- ^ Inc, Athira Pharma. "M3 Biotechnology Announces Name Change to Athira Pharma, Inc". www.prnewswire.com (Press release). Retrieved 2019-04-15.
{{cite press release}}:|last=has generic name (help) - ^ "Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma". FierceBiotech. Retrieved 2021-10-20.
- ^ Delgado, Diana Campelo (12 October 2020). "Dosing Starts in Phase 2/3 Trial of Athira's ATH-1017 for Alzheimer's". Retrieved 2021-08-30.
- ^ "Our Approach". Athira Pharma. Retrieved 2021-10-20.
- ^ "M3 Biotechnology Launches Clinical Trials for Alzheimer's Disease Drug Focused on Restoring Lost Connections in the Brain". Retrieved 2018-10-15.
- ^ Athira Pharma (2021-08-24). "A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease".
{{cite journal}}: Cite journal requires|journal=(help)